Engineering and Technology
| Open Access |
DOI: AI-Powered Regulatory Surveillance for Mitigating Pharmaceutical Manufacturer Product Hopping under the IRA
Pinaki Bose , Independent Researcher, USAAbstract
The Inflation Reduction Act (IRA) of 2022 aims to curb soaring pharmaceutical costs by mandating price negotiation for Qualifying Single Source Drugs (QSSDs) that have been on the market for 7 (small molecules) or 11 (biologics) years and lack generic competition. However, this time-based metric introduces a critical systemic vulnerability: Product Hopping (PH). PH is an established anticompetitive tactic wherein manufacturers introduce minor, non-therapeutic reformulations (a New Drug Application (NDA) or Biologics License Application (BLA)) solely to reset the negotiation clock, thereby extending their monopoly. Current reactive regulatory frameworks are insufficient to counteract these complex, data-driven manipulative strategies. This theoretical paper proposes an expert-level conceptual framework for an Artificial Intelligence (AI)-powered Regulatory Surveillance Architecture (RSA) within the Centers for Medicare & Medicaid Services (CMS). This RSA leverages predictive analytics, Natural Language Processing (NLP), and anomaly detection across multi-modal data streams—including patent filings, clinical trial documents, and market data—to quantify the economic and therapeutic rationale underlying reformulation, yielding a Probabilistic Intent Score (PIS). Central to the framework is the mandatory implementation of Explainable AI (XAI) to ensure that regulatory interventions, particularly those triggering high-stakes negotiation, are transparent, auditable, and legally defensible, meeting rigorous standards of administrative due process and governance.
Keywords
AI Governance, Product Hopping, Inflation Reduction Act (IRA), CMS, Predictive Analytics, Explainable AI, (XAI), Regulatory Informatics, Pharmaceutical Manipulation
References
FAQs about the Inflation Reduction Act's Medicare Drug Price Negotiation Program | KFF, https://www.kff.org/medicare/faqs-about-the-inflation-reduction-acts-medicare-drug-price-negotiation-program/
Medicare Drug Price Negotiation Program: Final Guidance, Implementation of Sections 1191 - CMS, https://www.cms.gov/files/document/ipay-2028-final-guidance.pdf
A Legal Test for the Pharmaceutical Company Practice of “Product Hopping” - AMA Journal of Ethics, https://journalofethics.ama-assn.org/article/legal-test-pharmaceutical-company-practice-product-hopping/2015-08
Explainable AI in Healthcare Risk Prediction - Censinet, https://www.censinet.com/perspectives/explainable-ai-in-healthcare-risk-prediction
PRODUCT HOPPING: A NEW FRAMEWORK - Michael A. Carrier* & Steve D. Shadowen - Congress.gov, https://www.congress.gov/116/meeting/house/109970/documents/HHRG-116-IF17-20190919-SD005.pdf
1 Michael A. Carrier Distinguished Professor Rutgers Law School Having Our Cake and Eating it Too: Five Things Congress Can Do,, https://www.congress.gov/117/meeting/house/112518/witnesses/HHRG-117-JU05-Wstate-CarrierM-20210429.pdf
Medicare Drug Price Negotiation Program: Revised Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act f - CMS, https://www.cms.gov/files/document/revised-medicare-drug-price-negotiation-program-guidance-june-2023.pdf
Natural Language Processing Applied to Clinical Documentation in Post-acute Care Settings: A Scoping Review - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC10792659/
The Role of Patents and Regulatory Exclusivities in Drug Pricing | Congress.gov, https://www.congress.gov/crs-product/R46679
COST OF GENERIC DRUG DEVELOPMENT AND APPROVAL FINAL - https: // aspe . hhs . gov., https://aspe.hhs.gov/sites/default/files/documents/20e14b66420440b9e726c61d281cc5a5/cost-of-generic-drugs-erg.pdf
Interpretable Optimization: Why and How We Should Explain Optimization Models - MDPI, https://www.mdpi.com/2076-3417/15/10/5732
The application of artificial intelligence in health financing: a scoping review - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC10626800/
Download and View Statistics
Copyright License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.